Phase 2 N=77 CC-4047 in Treating Patients With Myelofibrosis
Chronic Myeloproliferative Disorders · Secondary Myelofibrosis
Primary: Determine the Maximum Tolerated Dose of CC-4047 — 0; 0; 66 percentage of participants with DLT
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Opioid-related Disorders
Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…
N/A N=674 STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
Major Depressive Disorder · Alcohol Use Disorder
Primary: Quick Inventory of Depression- Self Report 16 — 9.3; 8.9 units on a scale
N/A N=5 Brain Stimulation for the Treatment of Tourette Syndrome
Tourette Syndrome
Primary: Mean Change in Yale Global Tic Severity Scale (YGTSS) Scores From Baseline to 6 Months Across All Study Participants Presented — -20.33; -14.05; 91; 92.5 units on a…
Phase 2 N=68 Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients
Phase 2 N=30 Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants
Phase 4 N=16 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
Focal Dystonia
Primary: Note Errors (Related to Errors in Duration) — 8.20; 5.79 msec — p==0.06
Phase 2 N=100 Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy
Unspecified Adult Solid Tumor, Protocol Specific · Vascular Access Device Complications
Primary: Port Failure Within 12 Months of Port Insertion — 16.1; 13.8 percentage of patients
Phase 2 N=10 Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation
Type 1 Diabetes
Primary: The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion — 4 participants
Phase 4 N=25 Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients
Acute Pain
Primary: Comparison of Pain Intensity Scores at 20 Minutes With the Baseline Pain Intensity Score During the Initial 6-hour Evaluation Period. — 14.3 millimeters — p=<0.0001
N/A N=86 Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty
Rotator Cuff Tear · Shoulder Impingement Syndrome
Primary: Western Ontario Rotator Cuff Index (WORC) — 80.5; 86.7 percentage of total score
Phase 4 N=316 Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c After 24 Weeks — -2.81; -2.02 percent — p=<0.0001
Phase 2 N=6 Sirolimus for Advanced Age-Related Macular Degeneration
Age-Related Macular Degeneration · Geographic Atrophy
Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…
Early Phase 1 N=21 Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) at 15 Minutes After the First Allergan Challenge — 2.90; 3.69 units on a scale — p=0.156
Phase 3 N=602 Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis
Adult Periodontitis
Primary: Change in Pocket Depth. — -1.4; -1.6; -1.4 mm